Shield Therapeutics (LON:STX) Trading Down 2.3% – Here’s What Happened

Shield Therapeutics plc (LON:STX)’s stock price was down 2.3% during trading on Wednesday . The company traded as low as GBX 10 and last traded at GBX 10.50. Approximately 1,713,937 shares were traded during trading, an increase of 11% from the average daily volume of 1,549,834 shares. The stock had previously closed at GBX 10.75.

Wall Street Analysts Forecast Growth

Separately, Peel Hunt reaffirmed a “buy” rating and issued a GBX 15 target price on shares of Shield Therapeutics in a research note on Friday, November 7th. One investment analyst has rated the stock with a Buy rating, According to MarketBeat, Shield Therapeutics has a consensus rating of “Buy” and a consensus target price of GBX 15.

Shield Therapeutics Stock Down 2.3%

The firm has a market capitalization of £111.49 million, a P/E ratio of -5.25 and a beta of 1.42. The firm’s 50 day moving average is GBX 9.20 and its two-hundred day moving average is GBX 7.10. The company has a debt-to-equity ratio of 3,691.50, a current ratio of 1.05 and a quick ratio of 2.16.

Shield Therapeutics Company Profile

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.